Top three stocks that saw heavy demand from buyers in the pre-opening session today

Gland Pharma Ltd, an S&P BSE company, surged 6.53 per cent to trade at Rs 2,837.55 apiece. Gland Pharma reported a strong Q1 FY27 performance, with consolidated revenue rising 20 per cent YoY to Rs 1,800.3 crore, while PAT jumped 47 per cent to Rs 317 crore. Adjusted EBITDA increased 37 per cent YoY to Rs 510.2 crore, with the margin improving to 28 per cent. The CDMO business grew 20 per cent and contributed 50 per cent of revenue, while B2B revenue rose 19 per cent. The company also launched four molecules in the US, filed three ANDAs and received seven approvals during the quarter.

Embassy Developments Ltd, an S&P BSE company, gained 4.95 per cent to trade at Rs 68.21 apiece. Embassy Developments reported a strong start to FY27, with Q1 pre-sales surging 338 per cent YoY to Rs 868 crore, while collections rose 54 per cent to Rs 496 crore. Area sold increased 135 per cent to 484,000 sq. ft., supported by strong demand in Bengaluru, where around 72 per cent of launched inventory was sold within six months. The company maintained its FY27 guidance of Rs 6,000 crore in pre-sales from owned developments and Rs 2,000 crore from development management projects. Net institutional debt stood at around Rs 3,363 crore, while cash and cash equivalents were around Rs 1,202 crore.

Aarti Pharmalabs Ltd, an S&P BSE company, advanced 4.44 per cent to trade at Rs 857.95 apiece. Aarti Pharmalabs reported a strong Q1 FY27 performance, with consolidated operational revenue rising 38.7 per cent YoY to Rs 535.8 crore, while EBITDA increased 39.3 per cent to Rs 132.6 crore. Consolidated PAT jumped 65.4 per cent YoY to Rs 76.1 crore, with PAT margin improving to 14.2 per cent. The company said its Xanthine derivatives capacity expansion to 9,600+ MTPA is being ramped up, while CDMO operations continue to expand with 22 customers and 57 active projects. Aarti Pharmalabs is targeting 15-18 per cent revenue and EBITDA CAGR over the next 3-4 years.